3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Multiple Myeloma
123
Recurrence
12
Neoplasms
8
Immunoglobulin Light-chain Amyloidosis
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms, Plasma Cell
5
Smoldering Multiple Myeloma
4
Lymphoma
4
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Plasmacytoma
2
Plasmablastic Lymphoma
2
Neoplasm, Residual
2
Myelodysplastic Syndromes
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Amyloidosis
2
Acute Kidney Injury
2
Triple Negative Breast Neoplasms
1
Proteostasis Deficiencies
1
Primary Myelofibrosis
1
Paraproteinemias
1
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Plasma Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
pembrolizumab
243
Carboplatin
211
Pemetrexed
177
Cisplatin
131
Paclitaxel
113
Nivolumab
101
Docetaxel
87
osimertinib
85
durvalumab
78
Specimen Handling
56
atezolizumab
55
Gemcitabine
52
Drug Therapy
52
Magnetic Resonance Spectroscopy
50
Radiosurgery
48
Radiotherapy
47
Ipilimumab
41
130-nm albumin-bound paclitaxel
39
cemiplimab
38
Bevacizumab
34
Cetuximab
30
tislelizumab
29
amivantamab
22
Taxes
22
Platinum Compounds
20
Blood Specimen Collection
20
Immunotherapy
18
Immune Checkpoint Inhibitors
18
Radiation
17
Erlotinib Hydrochloride
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
daratumumab
×
1 year
×
Clear all
NCT06015724
2026-05-15
DARANIVOVAX
Georgetown University
Phase 2
Recruiting
54 enrolled